Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
about
Metformin and metabolic diseases: a focus on hepatic aspectsMetformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2.Metformin improves survival in intensive care unit patients, but why?Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarctionCaloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo: a prospective randomized open, blinded-endpoint study.The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trialFenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model.IGF-1 and atherothrombosis: relevance to pathophysiology and therapy.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Targeting adenosine receptors in the development of cardiovascular therapeutics.Metformin therapy in diabetes: the role of cardioprotection.Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study.The role of succinate and ROS in reperfusion injury - A critical appraisal.Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effectsEffect of Preadmission Metformin Use on Clinical Outcome of Acute Respiratory Distress Syndrome among Critically Ill Patients with DiabetesThe pleiotropic effects of metformin: time for prospective studies.A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction.Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury.Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.What is the protective effect of metformin on rat ovary against ischemia-reperfusion injury?Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction.Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
P2860
Q28082736-C0232284-843B-4A15-A8D0-A2DBA90E32E8Q33632353-AC58E2CE-BCAB-4265-9DD9-F4D0ABB25250Q33753783-66099525-D60B-4419-8D28-DB8FA3F64E7FQ33867405-35273FE4-F5B9-4F2B-9704-ACF262832025Q35063002-B6430D4E-0437-44C1-9318-F02DC5088447Q35067242-0BE197B9-22DE-45FF-BAFB-9D0A281988CEQ35155185-55B1508F-1C16-48BA-81C5-6F0139C7B87AQ35377605-FD720663-D82E-423A-90AB-8EF6745B0AB7Q36297833-3612D16E-8591-405F-A882-D976F0BB3F70Q36742028-13666934-0382-4D3E-B1C8-4DC314B11DF3Q37829755-054E6526-416A-4A83-9417-7A7496B56FEAQ37926558-A92DA21C-DF07-440C-955A-E351D13DFFCAQ37990558-A263039A-EAE1-45D2-ACE8-3A5D5B7AFB47Q38083008-F0389762-40AF-4058-B928-3ED98EA02F0EQ38374396-D1CC68E7-15CE-4B0D-923E-3F58EDEFA4A3Q38682430-3B5E10F9-336F-4121-9998-BE649BC3442CQ39423100-958E384E-B763-4971-B244-864C737DBC23Q40630534-A67CB8A9-EE27-4782-BC7E-A87EEC2475F8Q41124317-ED59DFB2-40CA-4DAF-BC0E-2B51E63218A3Q41484964-BA161F33-5570-42AC-B848-35174937B623Q41498937-4F2B5FAA-CC56-4BED-80EC-6E4B664D2951Q41855554-C3B17374-90C9-4CE1-8324-48326F6B75C9Q43151456-223C3B96-603F-4217-A436-484A1146DA9EQ46260440-40B8D7AB-081F-4C3B-AC13-F2E8BB3C1CE8Q47196867-CD419DB0-8B57-4F1D-A02E-1850675E828CQ50798695-C1500607-7BD8-4737-9BA4-0FC846A24CCC
P2860
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@ast
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@en
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@nl
type
label
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@ast
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@en
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@nl
prefLabel
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@ast
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@en
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
@nl
P2093
P50
P1476
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor
@en
P2093
Gerard A Rongen
Luís Providência
Marta Paiva
Niels P Riksen
Paul Smits
P304
P356
10.1097/FJC.0B013E31819FD4E7
P577
2009-05-01T00:00:00Z